KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Operating Margin (2016 - 2025)

Historic Operating Margin for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to 101.13%.

  • Pacific Biosciences Of California's Operating Margin rose 591900.0% to 101.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 430.63%, marking a year-over-year decrease of 1945200.0%. This contributed to the annual value of 307.97% for FY2024, which is 1411700.0% down from last year.
  • Per Pacific Biosciences Of California's latest filing, its Operating Margin stood at 101.13% for Q3 2025, which was up 591900.0% from 112.79% recorded in Q2 2025.
  • Pacific Biosciences Of California's 5-year Operating Margin high stood at 101.13% for Q3 2025, and its period low was 1154.51% during Q1 2025.
  • Over the past 5 years, Pacific Biosciences Of California's median Operating Margin value was 191.64% (recorded in 2022), while the average stood at 258.42%.
  • Over the last 5 years, Pacific Biosciences Of California's Operating Margin had its largest YoY gain of 3754900bps in 2025, and its largest YoY loss of -9448700bps in 2025.
  • Pacific Biosciences Of California's Operating Margin (Quarter) stood at 179.56% in 2021, then plummeted by -77bps to 318.37% in 2022, then skyrocketed by 53bps to 150.02% in 2023, then tumbled by -160bps to 390.14% in 2024, then skyrocketed by 74bps to 101.13% in 2025.
  • Its last three reported values are 101.13% in Q3 2025, 112.79% for Q2 2025, and 1154.51% during Q1 2025.